EE524 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in Costa Rica
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.789
https://www.valueinhealthjournal.com/article/S1098-3015(23)03919-0/fulltext
Section Title :
Section Order :
10277
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03919-0&doi=10.1016/j.jval.2023.09.789